Guli Mi-Re, Wang Jun-Qi, Zhang Jie-Xiang, Deng Gang
Department of Urology, Friendship Hospital of Wulumuqi City, Wulumuqi, Xinjiang 830049, China.
Zhonghua Nan Ke Xue. 2006 Feb;12(2):120-2.
To investigate the association between the polymorphism of CYP17 gene and risk of prostate cancer in Chinese Vigurs men.
A case-control study including 31 patients with prostate cancer and 104 aged-matched controls was conducted. The polymorphism was investigated by PCR using DNA from peripheral blood lymphocytes. The transition (T-->C) in the risk allele (A2) produced a new recognition site for the restriction enzyme MSPAI I. Three genotypes of CYP17 gene (A1/A1, A1/A2, A2/A2) were determined and confirmed by sequencing.
Compared with male A1/A1 genotype, the odds ratios were 1.49 and 2.87 for the A1/A2 and A2/A2 genotypes (P =0.321, 0. 052, respectively). Comparison among 3 subgroups (division by genetypes) of prostate cancer patients, the PSA levels were not significantly different. But in the controls, PSA levels in A1/A2 group were higher but not significant than those in A1/A1 group (P = 0.062). Then, PSA levels in A2/A2 group were significantly higher than those A1/ A1 group (P = 0.018).
More frequency of A2/A2 genotype in prostate cancer than in the control may be associated with the morbidity of prostate cancer in Vigurs male population. Meanwhile, the significant high PSA levels in A2/A2 group also support the view.
探讨CYP17基因多态性与中国维吾尔族男性前列腺癌风险之间的关联。
开展一项病例对照研究，纳入31例前列腺癌患者和104例年龄匹配的对照。采用外周血淋巴细胞DNA通过聚合酶链反应（PCR）研究基因多态性。风险等位基因（A2）中的转换（T→C）产生了限制性内切酶MSPAI I的一个新识别位点。通过测序确定并证实了CYP17基因的三种基因型（A1/A1、A1/A2、A2/A2）。
与男性A1/A1基因型相比，A1/A2和A2/A2基因型的比值比分别为1.49和2.87（P分别为0.321、0.052）。前列腺癌患者的3个亚组（按基因型划分）之间比较，前列腺特异性抗原（PSA）水平无显著差异。但在对照组中，A1/A2组的PSA水平高于A1/A1组，但差异无统计学意义（P = 0.062）。然后，A2/A2组的PSA水平显著高于A1/A1组（P = 0.018）。
前列腺癌患者中A2/A2基因型的频率高于对照组，这可能与维吾尔族男性人群前列腺癌的发病有关。同时，A2/A2组显著较高的PSA水平也支持这一观点。
Zotero 插件